PT-141 While on a GLP-1: Libido, Timing, Evidence

What People Actually Report

Spend an hour in any GLP-1 forum and you will find both versions of this story, often in the same thread. One person says their sex drive came back for the first time in a decade once the weight started coming off: more energy, better sleep, a body they finally wanted to be seen in. The next person says desire flatlined around month two and has not returned, even though everything else about the medication is working. Both reports are common, both are real, and the honest starting point is that nobody can currently tell you which one you will get.

The published data is thinner than the volume of online discussion suggests. On the negative side, a 2025 analysis of the FDA adverse event reporting system found disproportionate reporting of male sexual dysfunction, including decreased libido and erectile dysfunction, among GLP-1 receptor agonist users. And a database study of insurance records found that non-diabetic men prescribed semaglutide for weight loss were more likely to later receive an erectile dysfunction or testosterone deficiency diagnosis than similar men who were not prescribed it.

Pourabhari Langroudi A, Chen AL, Basran S, et al. "Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data." Int J Impot Res, 2025. PMID 40240532. View study

Able C, Liao B, Saffati G, et al. "Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study." Int J Impot Res, 2025. PMID 38778151. View study

Now the caveats, because both of those findings are weaker than a headline makes them sound. Adverse event databases collect whatever people and clinicians choose to report, with no denominator and no control group, so they generate signals rather than rates. The insurance-record study shows an association, not causation, and men taking a weight loss medication see doctors more often, which by itself produces more diagnoses of everything. Meanwhile the older literature on weight loss points the other way: losing a large amount of weight, by surgery or by diet, generally improves sexual function and raises testosterone in men. So the evidence base is genuinely mixed, and anyone who tells you semaglutide reliably kills libido, or reliably restores it, is ahead of the data.

Why Libido Shifts During GLP-1 Weight Loss

The hardest part of this question is attribution. A person on semaglutide or tirzepatide is not just taking a drug. They are eating far less than they used to, losing weight quickly, sometimes nauseated, sometimes tired, and watching their body change faster than their self-image can keep up. Every one of those things can move libido on its own. Sorting out which one is responsible in your case matters, because the fixes are different.

The deficit itself. A sustained, steep energy deficit lowers energy for everything, and sex is one of the first discretionary expenditures the body cuts. This is not specific to GLP-1s. Dieters and bariatric surgery patients report the same thing during rapid-loss phases. The GLP-1 version is simply more sustained, because the medication makes a deep deficit easy to maintain for months without the hunger that usually forces a break.

Mood. Low sexual desire is a core symptom of depression, and it is also a known side effect of the SSRIs and SNRIs many people are already taking. If mood has dipped alongside libido, the libido is usually the symptom, not the problem. This is worth taking seriously rather than treating around.

Hormones, which mostly move the other way. The intuitive story, that the drug is tanking testosterone, is largely backwards for men with obesity. Excess adipose tissue suppresses the male hormonal axis, and a meta-analysis by Corona and colleagues found that weight loss raises testosterone, with larger losses producing larger rises, alongside increases in SHBG. In other words, the weight loss most people achieve on a GLP-1 should, on average, push male hormones in a favorable direction. Hormonal decline can still happen in an individual, which is why labs are worth checking, but it is the less likely explanation, not the default one.

Corona G, Rastrelli G, Monami M, et al. "Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis." Eur J Endocrinol, 2013. PMID 23482592. View study

GI misery and timing. It is hard to feel desire while nauseated, and the days after a weekly injection or a dose increase are exactly when GLP-1 nausea peaks. Some of what gets reported as libido loss is really nausea scheduling. The gut side of the medication has its own playbook, covered in nausea and gut issues on a GLP-1 Read nextNausea & Gut Issues on GLP-1s 2026: What Actually HelpsGI side effects are the single biggest reason patients stop Ozempic, Wegovy, and Mounjaro. Why they happen, which simple changes resolve most cases, and when BPC-157 is the right add-on.Read article . There is also a stranger timing effect people describe: the body changes in months, but body image lags it by longer, and some people feel less desirable mid-transformation than they did before it started, even as everyone around them says the opposite.

What to Rule Out First

A clinic that wanted to sell you PT-141 would put the order form here. The more useful thing is a short list of checks that resolve a meaningful share of these cases without any new prescription at all.

One more check belongs on the list: the GLP-1 prescription itself. At PeRx, GLP-1 prescriptions run on 28-day cycles with a provider dose review each cycle, and a persistent side effect is exactly the kind of thing that review exists for. If the timeline of the libido change tracks a dose increase, say so there. Labs are also reasonable at this point, particularly testosterone in men, since a number settles the hormone question faster than speculation does.

What PT-141 Is and Is Not

If the checks above come back clean and low desire is the remaining problem, PT-141 is the option built for that specific complaint. PT-141 Explore PeRxPT-141On-Demand Intimacy EnhancementView peptide , also called bremelanotide, is a melanocortin-4 receptor agonist. It works centrally, activating MC4 receptors in the hypothalamus that sit on the brain circuitry of sexual desire and motivation. That puts it in a different category from Viagra-class drugs, which are PDE5 inhibitors acting on blood flow in the periphery and do nothing for wanting. The full head-to-head lives in PT-141 vs Viagra Read nextPT-141 vs Viagra: How They Work DifferentlyPT-141 targets desire in the brain (melanocortin receptors). Viagra targets blood flow (PDE5). Different mechanisms for different problems.Read article , and the deep dive on the molecule itself, including its genuinely odd tanning-research origin story, is the main PT-141 guide Read nextPT-141 (Bremelanotide): The Complete Guide to the Desire PeptideHow PT-141 works in the brain, its FDA approval, the clinical results, the honest nausea data, dosage protocols, and how it compares to Viagra and Cialis.Read article .

PT-141 is unusual among compounded peptides in one important way: an FDA-approved version of it exists. Bremelanotide was approved in 2019 under the brand name Vyleesi, for acquired, generalized hypoactive sexual desire disorder in premenopausal women. That approval rested on two randomized phase 3 trials in over 1,200 premenopausal women, which found statistically significant improvements in desire and reductions in desire-related distress, with modest effect sizes and nausea as the dominant side effect. Be precise about what that means for what PeRx prescribes: the trials and the approval belong to Vyleesi, the branded product. The PT-141 PeRx prescribes is compounded by a licensed 503A pharmacy against an individual prescription, has not been through FDA review, and is prescribed off-label for populations outside the approval, including men. Off-label prescribing of this kind is legal and routine, but it is a clinical judgment, not an FDA endorsement.

Kingsberg SA, Clayton AH, Portman D, et al. "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials." Obstet Gynecol, 2019. PMID 31599840. View study

Dhillon S. "Bremelanotide: First Approval." Drugs, 2019. PMID 31429064. View study

The evidence in men is older and smaller but real: in a placebo-controlled crossover study, PT-141's parent compound produced erections in 17 of 20 men with erectile dysfunction without sexual stimulation, and increased reported desire, which is what put the melanocortin pathway on the map for male use. Women on a GLP-1 who are asking this question should read the trial data in context in PT-141 for women Read nextPT-141 for Women: Low Libido, Vyleesi, and What to ExpectThe only FDA-approved medication that targets female sexual desire in the brain. Who it helps, the premenopausal HSDD approval, and how it compares to Addyi.Read article , since premenopausal women with HSDD are the one population where the evidence is randomized and controlled rather than extrapolated.

Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. "Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II." Int J Impot Res, 2000. PMID 11035391. View study

Set expectations honestly before the logistics. The effect sizes in the phase 3 trials were statistically significant but modest, and PT-141 helps a subset of users meaningfully rather than everyone somewhat. It is also on-demand and non-hormonal: it does not touch testosterone or estrogen, there is no daily schedule and no buildup period, and the standard advice is to judge your response over 6 to 8 uses. If nothing has changed by then, it is not your tool, and stopping costs nothing.

Using PT-141 Alongside a Weekly GLP-1

Separate prescriptions, separate decisions

PeRx prescribes both medications, which makes the practical questions concrete. They remain separate prescriptions and separate decisions: qualifying for one does not qualify you for the other, and each goes through its own provider review. PT-141 ships fully reconstituted and ready to use, given as a subcutaneous injection of 1.75 mg about 45 minutes before anticipated activity, at most once per 24 hours and roughly eight times per month. It is on-demand, not a daily protocol, and your PeRx provider will prescribe an optimal protocol based on your intake. The step-by-step mechanics, timing and injection technique included, are in how to use PT-141 Read nextHow to Use PT-141: Timing, Injection, and What to ExpectWhen to inject before activity, the step-by-step subcutaneous technique, how long the effects last, and how often you can dose.Read article .

The nausea-stacking question

This is the overlap that actually deserves planning, and almost nothing written about either drug addresses it. PT-141's most common side effect is nausea, reported by roughly 40% of trial participants, with flushing next at about 20%. GLP-1s cause nausea too, concentrated in the days after the weekly injection and in the weeks after a dose increase. Whether the two nauseas add together has never been studied. No interaction study of PT-141 with any GLP-1 exists, so what follows is practical reasoning, not trial data, and it is worth saying that plainly.

The reasoning is simple: do not schedule your most nausea-prone medication into your most nausea-prone window. In practice that means three things. First, let the GLP-1 titration settle before starting PT-141 at all, so a bad evening has one suspect instead of two. Second, favor the back half of your injection week, when GLP-1 GI effects are at their weekly low, rather than the day after the shot. Third, use the standard PT-141 mitigations, eating light around the dose and asking about a pre-dose anti-nausea medication such as ondansetron, which matter more when a second nausea-causing drug is in the background. The full side effect picture, rates and management included, is in PT-141 side effects Read nextPT-141 Side Effects: The Honest Numbers by DoseReal clinical-trial rates for nausea, flushing, headache, blood pressure, and skin darkening, how long each lasts, and the practical steps that reduce them.Read article .

Gastric emptying and blood pressure

Two quieter overlaps are worth knowing. Both drugs slow gastric emptying, GLP-1s as a core mechanism and PT-141 transiently for a few hours after a dose. The practical consequence is for oral medications: anything time-sensitive you swallow near a PT-141 dose may absorb slower than usual, on top of the baseline slowing from the GLP-1, so separate critical oral medications from the PT-141 dose by several hours. And PT-141 briefly raises blood pressure, about 6 mmHg systolic and 3 mmHg diastolic on average, resolving within roughly 8 to 12 hours. That rise is why uncontrolled hypertension and cardiovascular disease are contraindications, why dosing is capped at once per 24 hours, and why cardiovascular history is part of the prescribing review. It is also, historically, why an intranasal formulation of bremelanotide studied in the 2000s was abandoned: nasal delivery produced erratic levels and worse blood pressure spikes. That formulation is a piece of research history, not a product. PeRx ships PT-141 only as a subcutaneous injection.

If your bigger question is what else people add alongside a GLP-1, and which additions have any evidence behind them, the tiered ranking in peptides to take with a GLP-1 Read nextPeptides to Take With a GLP-1: The EvidenceSearch this question and you get a stack. Every result recommends four or five peptides, none of them ranks the options, and none of them tells you which ones have human data behind them. This page sorts the same list into three tiers and says out loud which tier each one lands in.Read article is the decision layer above this page. PT-141 mostly sits outside that conversation, because it is not a body-composition or metabolic add-on. It is aimed at one specific complaint, which is exactly why it is worth considering only when that complaint is actually yours.

Who Should Skip It

Common Questions